[ad_1]
Conjunctivitis is also known as the pink eye because inflammation of the conjunctiva of the eye due to infection makes the white part of the eye appear. red or pink eye. Neonatal conjunctivitis is also known as Opthalmia Neonatorum. Neonatal conjunctivitis occurs in infants during the first 28 days of birth. It is usually acquired during the passage of the newborn into the infected birth canal. Neonatal conjunctivitis caused by non-sexually transmitted bacteria is less common than that caused by sexually transmitted organisms. Some of the common microorganisms that cause infection include Chlamydia trachomatis, Staphylococcus aureus, Staphylococcus epidermis, Esterichia coli, Neisseria gonorrhoea, other Gram-negative bacteria, and Herpes simplex virus
. Neonatal conjunctivitis can be caused not only by bacteria but also by chemical agents and viral agents. Final laboratory tests are needed for the diagnosis and identification of the causative organism. However, prophylactic treatment could be used to reduce the incidence of neonatal conjunctivitis, including the use of silver nitrate that could prevent infection in the newborn.
Request Report Sample @ https://www.persistencemarketresearch.com/products/23158
Conduct Factor of Neonatal Therapeutic Conjunctivitis
L & # 39; Rising birth rate around the world is driving the growth of neonatal conjunctivitis therapy market. In addition, the increase in the prevalence of infectious diseases, especially neonatal conjunctivitis, also leads to market growth. Increased awareness and screening of pregnant women for sexually transmitted diseases increases the treatment and precautionary rate for neonatal conjunctivitis by stimulating the growth of the neonatal conjunctivitis market. Increasing R & D investment in the development of new drugs is also fueling the growth of the neonatal conjunctivitis therapeutics market.
Neonatal Therapeutic Conjunctivitis
Chemically induced neonatal conjunctivitis usually cures alone and therefore requires no treatment. . Given the high incidence of neonatal conjunctivitis, especially with Chlamydia conjunctivitis, systemic therapy is usually chosen in such cases. A 14-day erythromycin treatment is prescribed to most patients. Although macrolide antibiotics such as azithromycin, clarithromycin, and roxithromycin may be more effective in cases of Chlamydia infection, they are not well studied in neonatal conjunctivitis. Gonococcal conjunctivitis in neonates may be treated with ceftriaxone administered intramuscularly or intravenously. Herpetic conjunctivitis in newborns can be treated using a topical solution of trifluridine
Regional Market Outlook
Request for Analysis Report @ [19659002OverallthetherapeuticmarketforneonatalconjunctivitiscanbedividedintoNorthAmericaLatinAmericaEuropeAsia-PacificandtheMiddleEastandAfricaNorthAmericadominatesthemarketforneonatalconjunctivitistherapyThehighprevalenceofsexuallytransmitteddiseasesandincreasedawarenessofneonatalconjunctivitisaresomeofthekeydriversofmarketgrowthinNorthAmericaTheAsia-PacificmarketisexpectedtogrowrapidlyastheregionisaverylucrativemarketforneonatalconjunctivitistreatmentsThisisalsoduetotheprevalenceofinfectionandpoorsanitationindevelopingcountries
Prospects for Competition
Examples of some of the major players in the non-union fracture market are Merck & Co Inc., Akorn Inc., Pfizer, Bayer AG and others.
Visit For TOC @ https://www.persistencemarketresearch.com/toc/23158
Display View:
8
Source link
